BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, Nakamuta M, Enjoji M. Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther 2013; 4(3): 54-60 [PMID: 23919217 DOI: 10.4292/wjgpt.v4.i3.54]
URL: https://www.wjgnet.com/2150-5349/full/v4/i3/54.htm
Number Citing Articles
1
Daniel Pineda-Tenor, Mónica García-Álvarez, María A. Jiménez-Sousa, Sonia Vázquez-Morón, Salvador Resino. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysisJournal of Translational Medicine 2015; 13(1) doi: 10.1186/s12967-015-0682-y
2
Mohammad Pouryasin, Maryam Keshvari, Heidar Sharafi, Seyed Moayed Alavian, Bita Behnava, Seyed Ehsan Alavian, Ali Pouryasin. The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis CHepatitis Monthly 2016; 16(2) doi: 10.5812/hepatmon.35278
3
Antonio D'Avolio, Jessica Cusato, Amedeo De Nicolò, Sarah Allegra, Giovanni Di Perri. Pharmacogenetics of Ribavirin-Induced Anemia in Hcv PatientsPharmacogenomics 2016; 17(8): 925 doi: 10.2217/pgs.16.22